Here are the 8-K filings from Kardigan, Inc. (KARD) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An 8-K covers material events a company has to report between its quarterly reports, so if you follow KARD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KARD filings page.
Kardigan, Inc. completed enrollment of 156 participants in its Phase 2b KATALYST-AV trial of ataciguat for aortic stenosis. The primary endpoint, aortic valve calcium, will be assessed at Week 48 alongside aortic valve area and measures of cardiac structure and function; the company will conduct an internal interim analysis at Week 24. The protocol amendment was made under blinded conditions, without review of unblinded efficacy data, and was not prompted by a safety finding.
A retrospective analysis of approximately 45,000 people with mild-to-moderate aortic stenosis found approximately 27% progressed rapidly, defined as an aortic valve area decline of at least 0.1 cm² per year. Patients with signs of cardiac damage on routine echocardiography were more likely to progress rapidly, and rapid progression predicted higher rates of valve replacement, hospitalization and worsening heart failure. The attached release expects Week 48 topline data in the second half of 2027, while the 8-K narrative separately says second half of 2026; the release also expects a Phase 3 plans update in the first half of 2027.
Kardigan, Inc. (KARD) appointed Kristin Reinke as a Class I director, effective September 29, 2026. She will chair the Audit Committee through the 2027 annual meeting of stockholders, unless she earlier dies, resigns, or is removed. The board determined that Reinke is independent under Nasdaq Global Market listing standards and qualifies as a financial expert under SEC rules; David Meeker will remain on the committee.
Doug Giordano resigned from the board and Audit Committee on September 29, 2026. Reinke, currently Google’s vice president of finance, will receive an initial new director grant of non-qualified stock options valued at $650,000, plus cash compensation for board and committee service under Kardigan’s Non-Employee Director Compensation Policy.
Kardigan, Inc. reported second quarter 2026 results and progress across three late-stage cardiovascular programs built on its Prolaio data platform. The company is running adaptive or Phase 2/3 trials for danicamtiv in genetic dilated cardiomyopathy, ataciguat in calcific aortic valve stenosis, and tonlamarsen in acute severe hypertension, with topline data for all three expected in the first half of 2027.
Kardigan completed an initial public offering in June 2026 with aggregate gross proceeds of $460 million, contributing to cash, cash equivalents and investments of $660.7 million as of June 30, 2026, up from $335.5 million at year-end 2025. This cash position is expected to fund multiple clinical data readouts and initiation of Phase 3 trials across the pipeline. Operating expenses rose sharply, including research and development of about $56.4 million versus $35.8 million a year earlier and a $43.5 million change in fair value of contingent milestone liabilities, driving a net loss of $116.2 million compared with $57.4 million in the prior-year quarter.
Kardigan, Inc. adopted a third amended and restated certificate of incorporation in connection with its initial public offering. The new charter authorizes 700,000,000 shares of common stock, including 500,000,000 voting shares and 200,000,000 non-voting shares, plus 10,000,000 shares of undesignated preferred stock that the board may issue in series.
The charter also removes prior preferred stock series and ends stockholder rights to act by written consent or to call special meetings. Kardigan simultaneously implemented amended and restated bylaws that set formal meeting procedures, advance notice rules for proposals and director nominations, and align with the updated charter.